Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology

Abstract Background Extensive research has underscored the criticality of preserving diversity and equilibrium within the gut microbiota for optimal human health. However, the precise mechanisms by which the metabolites and targets of the gut microbiota exert their effects remain largely unexplored....

Full description

Saved in:
Bibliographic Details
Main Authors: Weiguo Yao, Jinlin Huo, Jing Ji, Kun liu, Pengyu Tao
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Molecular Medicine
Subjects:
Online Access:https://doi.org/10.1186/s10020-024-01033-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850102831403499520
author Weiguo Yao
Jinlin Huo
Jing Ji
Kun liu
Pengyu Tao
author_facet Weiguo Yao
Jinlin Huo
Jing Ji
Kun liu
Pengyu Tao
author_sort Weiguo Yao
collection DOAJ
description Abstract Background Extensive research has underscored the criticality of preserving diversity and equilibrium within the gut microbiota for optimal human health. However, the precise mechanisms by which the metabolites and targets of the gut microbiota exert their effects remain largely unexplored. This study utilizes a network pharmacology methodology to elucidate the intricate interplay between the microbiota, metabolites, and targets in the context of DM, thereby facilitating a more comprehensive comprehension of this multifaceted disease. Methods In this study, we initially extracted metabolite information of gut microbiota metabolites from the gutMGene database. Subsequently, we employed the SEA and STP databases to discern targets that are intricately associated with these metabolites. Furthermore, we leveraged prominent databases such as Genecard, DisGeNET, and OMIM to identify targets related to diabetes. A protein-protein interaction (PPI) network was established to screen core targets. Additionally, we conducted comprehensive GO and KEGG enrichment analyses utilizing the DAVID database. Moreover, a network illustrating the relationship among microbiota-substrate-metabolite-target was established. Results We identified a total of 48 overlapping targets between gut microbiota metabolites and diabetes. Subsequently, we selected IL6, AKT1 and PPARG as core targets for the treatment of diabetes. Through the construction of the MSMT comprehensive network, we discovered that the three core targets exert therapeutic effects on diabetes through interactions with 8 metabolites, 3 substrates, and 5 gut microbiota. Additionally, GO analysis revealed that gut microbiota metabolites primarily regulate oxidative stress, inflammation and cell proliferation. KEGG analysis results indicated that IL-17, PI3K/AKT, HIF-1, and VEGF are the main signaling pathways involved in DM. Conclusion Gut microbiota metabolites primarily exert their therapeutic effects on diabetes through the IL6, AKT1, and PPARG targets. The mechanisms of gut microbiota metabolites regulating DM might involve signaling pathways such as IL-17 pathways, HIF-1 pathways and VEGF pathways.
format Article
id doaj-art-64c7ca7816a244bcb1ea8e38a30ac856
institution DOAJ
issn 1528-3658
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series Molecular Medicine
spelling doaj-art-64c7ca7816a244bcb1ea8e38a30ac8562025-08-20T02:39:40ZengBMCMolecular Medicine1528-36582024-12-0130111210.1186/s10020-024-01033-0Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacologyWeiguo Yao0Jinlin Huo1Jing Ji2Kun liu3Pengyu Tao4Department of Nephrology, Jinshan District Central Hospital, Shanghai University of Medicine & Health SciencesInstitute of Precision Medicine, The First Affiliated Hospital of Shantou University Medical CollegeDepartment of Emergency, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineDepartment of Nephrology, Jinshan District Central Hospital, Shanghai University of Medicine & Health SciencesDepartment of Nephrology, Seventh People’s Hospital, Shanghai University of Traditional Chinese MedicineAbstract Background Extensive research has underscored the criticality of preserving diversity and equilibrium within the gut microbiota for optimal human health. However, the precise mechanisms by which the metabolites and targets of the gut microbiota exert their effects remain largely unexplored. This study utilizes a network pharmacology methodology to elucidate the intricate interplay between the microbiota, metabolites, and targets in the context of DM, thereby facilitating a more comprehensive comprehension of this multifaceted disease. Methods In this study, we initially extracted metabolite information of gut microbiota metabolites from the gutMGene database. Subsequently, we employed the SEA and STP databases to discern targets that are intricately associated with these metabolites. Furthermore, we leveraged prominent databases such as Genecard, DisGeNET, and OMIM to identify targets related to diabetes. A protein-protein interaction (PPI) network was established to screen core targets. Additionally, we conducted comprehensive GO and KEGG enrichment analyses utilizing the DAVID database. Moreover, a network illustrating the relationship among microbiota-substrate-metabolite-target was established. Results We identified a total of 48 overlapping targets between gut microbiota metabolites and diabetes. Subsequently, we selected IL6, AKT1 and PPARG as core targets for the treatment of diabetes. Through the construction of the MSMT comprehensive network, we discovered that the three core targets exert therapeutic effects on diabetes through interactions with 8 metabolites, 3 substrates, and 5 gut microbiota. Additionally, GO analysis revealed that gut microbiota metabolites primarily regulate oxidative stress, inflammation and cell proliferation. KEGG analysis results indicated that IL-17, PI3K/AKT, HIF-1, and VEGF are the main signaling pathways involved in DM. Conclusion Gut microbiota metabolites primarily exert their therapeutic effects on diabetes through the IL6, AKT1, and PPARG targets. The mechanisms of gut microbiota metabolites regulating DM might involve signaling pathways such as IL-17 pathways, HIF-1 pathways and VEGF pathways.https://doi.org/10.1186/s10020-024-01033-0DiabetesGut microbiotaMetabolitesNetwork pharmacologyKidney disease
spellingShingle Weiguo Yao
Jinlin Huo
Jing Ji
Kun liu
Pengyu Tao
Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
Molecular Medicine
Diabetes
Gut microbiota
Metabolites
Network pharmacology
Kidney disease
title Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
title_full Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
title_fullStr Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
title_full_unstemmed Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
title_short Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
title_sort elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
topic Diabetes
Gut microbiota
Metabolites
Network pharmacology
Kidney disease
url https://doi.org/10.1186/s10020-024-01033-0
work_keys_str_mv AT weiguoyao elucidatingtheroleofgutmicrobiotametabolitesindiabetesbyemployingnetworkpharmacology
AT jinlinhuo elucidatingtheroleofgutmicrobiotametabolitesindiabetesbyemployingnetworkpharmacology
AT jingji elucidatingtheroleofgutmicrobiotametabolitesindiabetesbyemployingnetworkpharmacology
AT kunliu elucidatingtheroleofgutmicrobiotametabolitesindiabetesbyemployingnetworkpharmacology
AT pengyutao elucidatingtheroleofgutmicrobiotametabolitesindiabetesbyemployingnetworkpharmacology